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Edited by Qi-Qun TangDiabetes mellitus (DM) causes injury to tissues and organs,
including to the heart and kidney, resulting in increased
morbidity and mortality. Thus, novel potential therapeutics are
continuously required to minimize DM-related organ damage.
We have previously shown that dipeptidyl peptidase III
(DPPIII) has beneficial roles in a hypertensive mouse model,
but it is unknown whether DPPIII has any effects on DM. In
this study, we found that intravenous administration of re-
combinant DPPIII in diabetic db/db mice for 8 weeks sup-
pressed the DM-induced cardiac diastolic dysfunctions and
renal injury without alteration of the blood glucose level. This
treatment inhibited inflammatory cell infiltration and fibrosis
in the heart and blocked the increase in albuminuria by
attenuating the disruption of the glomerular microvasculature
and inhibiting the effacement of podocyte foot processes in the
kidney. The beneficial role of DPPIII was, at least in part,
mediated by the cleavage of a cytotoxic peptide, named Peptide
2, which was increased in db/db mice compared with normal
mice. This peptide consisted of nine amino acids, was a
digested fragment of complement component 3 (C3), and had
an anaphylatoxin-like effect determined by the Miles assay and
chemoattractant analysis. The effect was dependent on its
interaction with the C3a receptor and protein kinase C-medi-
ated RhoA activation downstream of the receptor in endothe-
lial cells. In conclusion, DPPIII plays a protective role in the
heart and kidney in a DM animal model through cleavage of a
peptide that is a part of C3.
Diabetes mellitus (DM) is globally one of the most common
chronic diseases, characterized by high blood glucose and
insufficient insulin production and/or supply (1, 2). The
number of DM patients is increasing in both developed and
developing countries; 23 million adults have been diagnosed
with DM in the United States, and there are 415 million adults
with DM diagnoses globally (3, 4). DM causes severe damage‡ These authors were contributed equally to this study.
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BY license (http://creativecommons.org/licenses/by/4.0/).in several organs and tissues, including the kidney, heart, blood
vessels, and nerves (5), which frequently leads to life-
threatening events, such as myocardial infarction. When DM
is classified by type 1 DM (T1DM) and type 2 DM (T2DM) of
which pathogenetic processes are different, mortality and
incidence of cardiovascular diseases including renal dysfunc-
tion are higher in T2DM than in T1DM (6). These outcomes
are also observed in younger DM patients: among T1DM and
T2DM patients with similar age of onset between 15 and
30 years, T2DM is associated with a greater mortality and
more cardiovascular diseases compared with T1DM (7). Thus,
more intensive care and therapy are needed in T2DM patients.
Among DM-induced complications, diabetic cardiomyopa-
thy and diabetic kidney disease (DKD) often occur from the
early stage and/or short duration after onset of DM and seem
to be hallmarks to presume the progression and severity of
DM (8, 9). Diabetic cardiomyopathy is defined as DM-related
ventricular dysfunction that occurs in the absence of coronary
atherosclerosis or hypertension (10), and diastolic dysfunction
is considered to be the indicator for diabetic cardiomyopathy
(11). The prevalence of diastolic dysfunction is higher in pa-
tients with T2DM than in those with T1DM, suggesting an
increased risk of cardiac failure in T2DM (12, 13). Albumin-
uria is a useful symptom to define DKD and predict its pro-
gression (14, 15). Pathologically, glomerular basement
membrane thickening and mesangial matrix expansion occur
in the middle to late stages of DKD, leading to renal fibrosis
and glomerulosclerosis (16, 17). Similar to diabetic cardio-
myopathy, the incidence of DKD in T2DM is higher than that
in T1DM (18, 19).
Strict control of blood glucose is important in preventing
DM-induced complications in both T1DM and T2DM
(20–25). However, based on more severe prognosis in T2DM
than in T1DM even when they follow the currently available
intensive blood glucose management for DM, continuing
development of therapies in addition to the blood-glucose-
lowering therapy is required to completely cure DM and
prevent DM-related physical dysfunctions. To date, there are
several reports showing that peptides derived fromJ. Biol. Chem. (2021) 296 100761 1
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DPPIII for diabetic heart and kidneyendogenous proteins in the serum exhibit cytotoxicity and
exacerbate the prognosis of diseases (26, 27). In this context,
we consider that one of the potential approaches to develop
the glycemic control-independent new therapy for T2DM
would be the identification of harmful circulating peptides
increased in T2DM and the exploration of methods and
techniques to exclude them from the circulatory system.
Dipeptidyl peptidase III (DPPIII) is an aminopeptidase that
cleaves specific dipeptides from the N terminus of relatively
small peptides that consist of approximately less than 12
amino acids (28). In contrast to DPPIV, which digests
glucagon-like peptide-1 (GLP-1) and is a target for DM ther-
apy, DPPIII does not cleave GLP-1 and displays no effect on
glycemic control. Instead, DPPIII digests some bioactive pep-
tides, including angiotensins, and enkephalins (29), which
consist of less than eight amino acids. We have determined the
kinetic characteristics of DPPIII for angiotensin II (AngII) and
IV and demonstrated the blood-pressure-lowering effect of
DPPIII on hypertensive mice by reducing the plasma AngII
concentration (30). However, it remains unknown whether
DPPIII exhibits any effects on DM.
In this study, we used the diabetic db/db mouse as a T2DM
model (31) and investigated how intravenously administered
DPPIII functions in the diabetic mice. Although DPPIII
administration did not affect the blood glucose level, it
significantly improved DM-induced cardiac and renal dys-
functions. We also identified the peptide that was cleaved by
DPPIII. Intravenous injection of this peptide in db/db mice
exacerbated the organ damage. Furthermore, we explored the
mechanism by which this takes place.
Results
No change in obesity, hyperglycemia, hemodynamics, or
plasma lipid profiles in db/db mice after DPPIII administration
We first examined whether DPPIII administration affected
any phenotypes of the diabetic model mice. The db/db mice
were intravenously administered with DPPIII (10 μg/g body
weight) or phosphate-buffered saline (PBS) as a control for
8 weeks as previously described (30). As a reference, PBS-
infused C57BL/6 mice were observed simultaneously. At the
beginning of the experiment (0 weeks), db/db mice aged
8 weeks displayed significant obesity and hyperglycemia
compared with C57BL/6 mice (Fig. S1, A and B). Body weight
and the blood glucose level gradually increased in db/db mice
during the experimental period, and this increase was unaf-
fected by DPPIII treatment (Fig. S1, A and B). Hemodynamics
monitored by heart rate and systolic blood pressure (BP) was
also unchanged after the DPPIII injection as well as during the
experimental period (Fig. S1, C–F). This is consistent with our
previous findings that DPPIII-mediated BP-lowering effects
were observed specifically in AngII-stimulated hypertensive
mice, but not in normotensive mice (30). We further
confirmed that DPPIII treatment displayed no effects on
plasma cholesterol or triglyceride levels in db/db mice, which
were significantly higher than those in C57BL/6 mice (Fig. S1,
G and H).2 J. Biol. Chem. (2021) 296 100761Prevention of diastolic dysfunction in the heart by DPPIII
administration
Cardiac function during DPPIII administration was moni-
tored by echocardiography. As previously reported (32, 33), we
found that db/db mice displayed normal left ventricular (LV)
dimensions and systolic functions without hypertrophy, which
were similar to C57BL/6 mice, and that the parameters were
not significantly changed during the 8-week DPPIII treatment
(Fig. 1, A–D, Fig. S2, and Movies S1–S3). In contrast, the
diastolic functions in the heart assessed by pulse-wave and
tissue Doppler modes of echocardiography were impaired in
PBS-infused db/db mice, compared with PBS-infused C57BL/6
mice (Fig. 1, E–G, Fig. S2, A and B, and Movies S1 and S2).
Notably, DPPIII treatment improved the impaired diastolic
functions in db/db mice (Fig. 1, E–G, Fig. S2C, and Movie S3).
Hematoxylin and eosin (H-E) and wheat germ agglutinin
(WGA) staining demonstrated that the morphology and size of
cardiomyocytes were similar between C57BL/6 and db/db
mice and were unchanged by DPPIII treatment (Fig. 1, H and
I), whereas compared with the C57BL/6 mouse heart, the
fibrosis was increased in the db/db mouse heart, which was
reduced by DPPIII treatment (Fig. 1, J and K). Cardiac fibrosis
is induced by enhanced inflammation with infiltrated mono-
cytes and macrophages into the myocardium (34). We found
increased infiltration of CD68-positive inflammatory cells in
the PBS-infused db/db than C57BL/6 mouse hearts, which was
reversed in the db/db mouse heart when treated with DPPIII
(Fig. 1, L and M). These results suggest that DPPIII prevents
DM-related diastolic dysfunction by reducing inflammation
and fibrosis in the heart.
Protective effects of DPPIII on DKD
One of the symptoms of DKD is albuminuria (14, 35). Even
at the beginning of the experiment, db/db mice exhibited a
higher level of urine albumin excretion than C57BL/6 mice,
and the excretion was markedly elevated in PBS-infused db/db
mice, whereas the increase was blocked by DPPIII treatment
(Fig. 2, A and B). In parallel with the progression of albu-
minuria, desmin deposition, an indicator for kidney injury, in
the glomeruli was promoted in PBS-infused db/db mice, which
was almost totally reversed by DPPIII treatment (Fig. 2, C and
D). Furthermore, the glomerular microvasculature detected by
CD31-positive endothelial cell staining was disrupted in PBS-
infused db/db mice, compared with PBS-infused C57BL/6
mice, and that this disruption was recovered in DPPIII-treated
db/db mice (Fig. 2E). Observation of ultrastructures of the
glomeruli clearly depicted the effacement of podocyte foot
processes in PBS-infused db/db mice, and the podocyte
damage was ameliorated by DPPIII treatment (Fig. 2F). These
results suggest that DPPIII functions as a suppressor of DKD.
Identification of DPPIII-cleaved cytotoxic peptides in db/db
mouse plasma
Because DPPIII treatment induced cardio- and reno-
protection in the diabetic mice independently of the ameliora-
tion of hyperglycemia, we hypothesized that DPPIII might
Figure 1. Cardioprotective effect of DPPIII on diabetic mice. A–G, echocardiographic measurement of each parameter analyzed every 4 weeks during the
8-weeks experimental period. H, hematoxylin-eosin (H-E) and WGA staining of the mouse heart after the 8-week treatment. I, summary graph of cardiomyocyte
sizemeasured byWGA staining. J, cardiac fibrosis detected by Sirius red staining after the 8-week treatment. The dotted squarewas enlarged and shown below. K,
summary graph of the percentage of fibrotic areas in the cardiac sections. L, confocal images of CD68 immunostaining. Cell membrane and nuclei were
counterstainedwithWGA andDAPI, respectively.M, summary graph of the number of CD68-positive cells. Scale bars: 50 μm (H and L) and 200 μm (J). InA–G, two-
way ANOVAwas applied for comparing the data between groups, and one-way ANOVAwas applied for comparing the results at week 0 with those at other time
points; in I, K, andM, one-way ANOVAwas used to compare the data of each group. *p< 0.05 and **p< 0.01 versus C57BL/6mice; ††p< 0.01 versus 0 weeks; §p<
0.05 and §§p< 0.01 versusPBS-infuseddb/dbmice. e’/a’, ratio of early to atrial diastolicmitral annular velocities; E/e’, ratio of peak transmitral velocity of early inflow
to early diastolic mitral annular velocity; E/A, ratio of peak transmitral velocity of early inflow to atrial inflow; EF, ejection fraction; LVDd, LV diastolic diameter;
LVPWd, left ventricular posterior wall diastolic thickness.
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Figure 2. Reno-protective effect of DPPIII on diabetic mice. A, representative Coomassie Brilliant Blue staining of urine samples after 8 weeks and
different amounts of bovine serum albumin (BSA). The urine samples from mice were collected for 24 h (1 day), and the proteins in the samples were
separated by SDS-PAGE. An arrowhead indicates urine albumin. BSA was used as a control. B, summary graph of the amount of excreted albumin for 1 day
in each group. C, confocal images of desmin and nephrin co-immunostaining in the glomeruli. Arrowheads indicate abnormal desmin deposition. D,
summary graph of the percentage of desmin-positive areas per glomerulus. E, confocal images of CD31 and podocin co-immunostaining in the glomeruli. F,
ultrastructures of the glomeruli observed by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Arrowheads indicate
damaged podocyte foot processes. Scale bars: 20 μm (C and E) and 1 μm (F). In B, two-way ANOVA was applied for comparing the data between groups, and
one-way ANOVA was applied for comparing the results at week 0 with those at other time points; in C, one-way ANOVA was used to compare the data of
each group. **p < 0.01 versus C57BL/6 mice; †p < 0.05 versus 0 weeks; §p < 0.05 and §§p < 0.01 versus PBS-infused db/db mice.
DPPIII for diabetic heart and kidneyeffectively cleave harmful cytotoxic peptides that are present in
db/db mouse blood. To explore the peptides, the whole pepti-
domics analysis was conducted using tandem mass spectrom-
etry, in which peptides derived from the plasma of PBS-infused
C57BL/6 mice, PBS-infused db/db mice, and DPPIII-treated db/
db mice were compared. In the comparison, we focused on the4 J. Biol. Chem. (2021) 296 100761short-length peptides consisting of ≤12 amino acids because of
the specificity of DPPIII digestion, and the lists of the peptides in
the threemouse groupswere shown in Supplemental Data 1 to 3.
Then, we used the following strategy to identify the target pep-
tide: (1) selecting the peptides that existed in the PBS-infused db/
db mouse plasma, but not in the PBS-infused C57BL/6 mouse
DPPIII for diabetic heart and kidneyplasma, (2) selecting the peptides of which amount (Area) was
higher in the PBS-infused db/db mouse plasma than in the PBS-
infused C57BL/6mouse plasma, (3) among the peptides thatmet
the criteria (1) or (2), selecting the peptides of which N-terminal
two amino acids were deleted or the peptides that were not
detected in the DPPIII-treated db/db mouse plasma, and then,
(4) selecting the peptides that have the arginine or tyrosine res-
iduewithin theN-terminal two amino acids because the peptides
cleaved by DPPIII include the residue (28). After performing
these procedures, three peptides remained (Table 1). Subse-
quently, we determined whether DPPIII could cleave these
peptides. Each peptide was incubated with DPPIII, and then, the
peptide with degraded products was separated by reversed-phase
liquid chromatography. Only Peptide 2 was rapidly and
completely cleaved by DPPIII, while the other peptides were not
or were ineffectively digested (Fig. 3, A–C). The plasma con-
centration of Peptide 2 in mice of each group was determined by
selected reaction monitoring (SRM). The concentration is
significantly higher in the plasma of PBS-infused db/db mice
comparedwith PBS-infusedC57BL/6mice and is clearly reduced
by administration of DPPIII in db/dbmice (Fig. 3D). As shown in
Table 1, Peptide 2 is a part of complement component 3 (C3) and
consists of nine amino acids, being 53% identical with C3f (17
amino acids), which is generated from C3b. C3f has been re-
ported to have anaphylatoxic biological activity such as C3a (36).
Cytotoxic role of Peptide 2 in the heart and kidney
We examined the in vivo cytotoxicity of Peptide 2 by
intravenous injection of this peptide (0.5 μg/g body weight)
into mice. As a control peptide, we selected a peptide that also
consists of nine amino acids (IAFSQYLQK) derived from
serum albumin and was present at the same level in the plasma
of both PBS-infused and DPPIII-treated db/db mice in the
peptidomics analysis as described above (datasets 2 and 3). The
control peptide was not digested by DPPIII (Fig. S3). The body
weight and blood glucose level in db/db mice increased simi-
larly during the experimental period with both the control
peptide and Peptide 2 treatments (Fig. S4, A and B). Hemo-
dynamics and plasma lipid profiles were also almost un-
changed and similar between the peptide treatments (Fig. S4,
C–H).
We then investigated the effect of Peptide 2 on the heart of
db/db mice. LV dimensions and systolic functions were
normal and preserved by Peptide 2 administration (Fig. 4, A–
D, Fig. S5, and Movies S4 and S5). However, cardiac diastolic
functions were further deteriorated by Peptide 2 administra-
tion, compared with the control peptide administration (Fig. 4,Table 1
Short-length peptides that existed in the plasma of PBS-infused db/db
Peptide Sequence Original protein n
1 RGVSAEYSF Sorting and assembly m
component 50 homo
2 RLLWENGNL Complement compone
3 RPHFLYPKSRLV ClusterinE–G, Fig. S5, and Movies S4 and S5). Similarly, cardiac fibrosis
and inflammatory cell infiltration were enhanced by Peptide 2
administration (Fig. 4, H–K). Peptide 2 also displayed harmful
effects on the kidney of db/db mice. The urine albumin
excretion was more abundant by Peptide 2 than the control
peptide injection (Fig. 5, A and B). Desmin deposition and
microvasculature disruption in the glomeruli were highly
enhanced by Peptide 2 injection, compared with the control
peptide injection (Fig. 5, C–E). In accordance with these re-
sults, ultrastructures of the glomeruli demonstrated remark-
able Peptide 2-induced damage to podocyte foot processes
(Fig. 5F). Peptide 2 administration in nondiabetic db/m mice
did not affect their body weight, blood glucose level, or he-
modynamics (Fig. S6, A–D). The deteriorative effects of Pep-
tide 2 on the organs in db/db mice were not observed in db/m
mice (Figs. S6, E–J, and S7). These results suggest that Peptide
2, which is a substrate of DPPIII, accelerates DM-related organ
damage and dysfunctions, particularly in the heart and kidney,
and that the peptide is less harmful in nondiabetic animals.
Mechanism of Peptide-2-induced cytotoxicity
To investigate how Peptide 2 induces toxicity in the heart
and kidney, we hypothesized that this peptide had
anaphylatoxin-like functions because of its representing a part
of C3f. The Miles assay demonstrated the marked induction of
vascular permeability on stimulation with Peptide 2 as well as
with histamine, a positive control, but not on control peptide
injection (Fig. 6A and B). Subsequently, chemoattractant ac-
tivity of Peptide 2 was examined using U937 macrophage-like
cells that were seeded onto a monolayer of human umbilical
vein endothelial cells (HUVECs) in the Transwell assay. Pep-
tide 2 stimulation in the lower chamber increased the number
of migrated U937 cells across the monolayer in a
concentration-dependent manner (Fig. 6C). We found that
Peptide 2 stimulation clearly promoted F-actin assembly in
HUVECs, compared with control peptide stimulation (Fig. 6, D
and E). Excessive F-actin assembly inside cells causes strong
contractility and high inward traction forces from the plasma
membrane (37, 38), physically inducing the breakdown of
intercellular junctions. Consistent with this, several gaps be-
tween HUVECs were observed by Peptide 2 stimulation
(Fig. 6D), thereby allowing transendothelial migration of the
U937 cells. These phenomena disappeared when peptides
derived from DPPIII-digested Peptide 2 were used (Fig. S8),
suggesting the specific contribution of Peptide 2, but not its
degraded peptides, to the phenomena. RhoA activity plays a
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Figure 3. Proteolytic activity of DPPIII on peptides identified in the plasma of diabetic mice. A–C, Peptide 1 (A), Peptide 2 (B), or Peptide 3 (C) was
incubated with DPPIII for the indicated times, and the cleaved products were analyzed by reversed-phase liquid chromatography. Arrows: Peptide 1 (A),
Peptide 2 (B), or Peptide 3 (C); arrowheads: cleaved products; *: nonspecific contaminant. D, plasma Peptide 2 concentration in the mice of each group was
determined by SRM. One-way ANOVA was used to compare the data of each group. **p < 0.01 versus C57BL/6 mice; §§p < 0.01 versus PBS-infused db/db
mice.
DPPIII for diabetic heart and kidneysignificantly increased the GTP-bound active RhoA in
HUVECs, whereas the control peptide stimulation had no ef-
fect (Fig. 6, F and G; Fig. S9).
We further examined how Peptide 2 transduced the signal
inside the endothelial cells to induce RhoA activation and F-
actin assembly by focusing on the association of Peptide 2 with6 J. Biol. Chem. (2021) 296 100761C3a receptor (C3aR), because C3f is considered to exert its
anaphylatoxic activity through C3aR (36). Following confir-
mation of C3aR knockdown in HUVECs by siRNA (siC3aR #2)
(Fig. 7A), fluorescein isothiocyanate (FITC)-conjugated Pep-
tide 2 was incubated with HUVECs. FITC-Peptide 2 attach-
ment on the cells detected by fluorescence microscopy was
Figure 4. Deterioration of cardiac diastolic function by Peptide 2 administration. A–G, echocardiographic measurement of each parameter analyzed
every 4 weeks during the 8-week experimental period. H, cardiac fibrosis detected by Sirius red staining after the 8-week treatment. The dotted square was
enlarged and shown below. I, summary graph of the percentage of fibrotic areas in the cardiac sections. J, confocal images of CD68 immunostaining. Cell
membrane and nuclei were counterstained with WGA and DAPI, respectively. K, summary graph of the number of CD68-positive cells. Scale bars: 200 μm (H)
and 50 μm (J). In A–G, two-way ANOVA was applied for comparing the data between groups, and one-way ANOVA was applied for comparing the results at
week 0 with those at other time points; in I and K, the data between the two groups were analyzed by Kolmogorov–Smirnov test. *p < 0.05 and **p < 0.01
versus Control peptide; ††p < 0.01 versus 0 week.
DPPIII for diabetic heart and kidney
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Figure 5. Peptide-2-mediated deterioration of renal function. A, representative Coomassie Brilliant Blue staining of urine samples after 8-week treatment
and different amounts of BSA. The urine samples from mice were collected for 24 h (1 day), and the proteins in the samples were separated by SDS-PAGE.
An arrowhead indicates urine albumin. B, summary graph of the amount of excreted albumin for 1 day in each group. C, confocal images of desmin and
nephrin co-immunostaining in the glomeruli. Arrowheads indicate abnormal desmin deposition. D, summary graph of the percentage of desmin-positive
areas per glomerulus. E, confocal images of CD31 and podocin co-immunostaining in the glomeruli. F, ultrastructures of the glomeruli observed by scanning
electron microscopy (SEM) and transmission electron microscopy (TEM). Arrowheads indicate highly damaged podocyte foot processes. Scale bar: 20 μm (C
and E) and 1 μm (F). In B, two-way ANOVA was applied for comparing the data between groups, and one-way ANOVA was applied for comparing the results
at week 0 with those at other time points; in D, the data between the two groups were analyzed by Kolmogorov–Smirnov test. *p < 0.05 versus Control
peptide; †p < 0.05 and ††p < 0.01 versus 0 week.
DPPIII for diabetic heart and kidneysignificantly reduced in C3aR-knockdown HUVECs, compared
with scramble RNA-transfected HUVECs (Fig. 7, B and C).
This suggests Peptide 2 binding to C3aR. RhoA activation and
U937 transendothelial migration induced by Peptide 2 were
almost completely inhibited by C3aR knockdown (Fig. 7, D–F;
Fig. S9). Because protein kinase C (PKC) functions down-
stream of C3aR (40, 41) and mediates the activation signal for
RhoA (42), the involvement of PKC in the Peptide-2-related
cytotoxic activity was investigated in HUVECs. Peptide 2
stimulation increased PKC phosphorylation, and the phos-
phorylation was diminished by C3aR knockdown (Fig. 7, G and
H; Fig. S9). Consequently, Peptide-2-induced RhoA activation
and U937 transendothelial migration were inhibited in the
presence of PKC inhibitor (Fig. 7, I–K; Fig. S9). We also found
that in the Miles assay, Peptide-2-stimulated vascular perme-
ability was inhibited by PKC inhibitor (Fig. 7L). These results8 J. Biol. Chem. (2021) 296 100761suggest that Peptide 2 utilizes the C3aR-PKC signaling
pathway to induce cytotoxicity, leading to DM-mediated organ
injury and failure.
Discussion
DM patients have a high mortality rate, mainly due to DM-
related heart and/or kidney failure (35, 43). Pathologically,
heart dysfunction exacerbates kidney damage, while renal
injury negatively affects cardiac function. This is clinically
referred to as cardiorenal syndrome, which displays mutual
deterioration between the heart and kidney and contributes to
the increased mortality (44). To reduce diabetic complications
in tissues and organs, particularly in the heart and kidney,
great effort has been made to develop effective medicines and
therapeutics for DM. Among these, much attention has
recently been paid to sodium-glucose cotransporter 2 (SGLT2)
Figure 6. Peptide-2-induced vascular permeability and RhoA activation in endothelial cells. A, miles assay to visualize the vascular permeability. Dotted
areas indicate the extravasated Evans blue. B, summary graphof Evans blue-positive area.C, migration activity of U937 cells seededon amonolayer of HUVECs in
a Transwell chamber. Histamine was used as the positive control. D, F-actin assembly in the HUVECs treated with Peptide 2 for the indicated times. F-actin was
stained with Alexa488-conjugated phalloidin. Cell membrane was stained with WGA. Stars indicate the gaps between cells. E, summary graph of phalloidin
intensity examined in (D). F, RhoA activity in HUVECs treated with Peptide 2 for the indicated times. The active form of RhoAwas pulled down using GST fusion
protein including GTP-bound RhoA-binding domain of mDia.G, summary graph of RhoA activity examined in (F). Scale bars: 2mm (A) and 20 μm (D). In B and E,
two-way ANOVA was applied for comparing the data between groups; in C, E and G, one-way ANOVA was used for comparing the results at 0 μg/ml or Time
0with those at other concentrations or time points. *p< 0.05 and **p< 0.01 versusControl peptide; †p< 0.05 and ††p< 0.01 versus 0 μg/ml, db/mor 0min. A.U.,
arbitrary units.
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Figure 7. Involvement of C3aR and protein kinase C in Peptide-2-induced activation of RhoA and vascular permeability. A, semiquantitative PCR to
monitor the knockdown efficiency of C3a receptor (C3aR) in HUVECs by siRNA against C3aR (siC3aR). B, FITC-Peptide 2 attachment on HUVECs observed by
fluorescent confocal microscopy. HUVECs were incubated with 200 μmol/l FITC-Peptide 2. C, summary graph of the intensity of FITC-Peptide 2 on HUVECs,
which were incubated with the indicated concentrations of FITC-Peptide 2. D, inhibition of Peptide-2-induced RhoA activation by knockdown of C3aR in
HUVECs. HUVECs were incubated with Peptide 2 for the indicated times. E, summary graph of RhoA activity examined in (D). F, inhibition of Peptide-2-
induced U937 cell migration through a HUVEC monolayer coating in the Transwell chamber by knockdown of C3aR in HUVECs. G, protein kinase C
(PKC) phosphorylation (activation) induced by Peptide 2 with or without siC3aR in HUVECs. H, summary graph of the P-PKC/GAPDH density ratio. I, RhoA
activity induced by Peptide 2 in the presence and absence of PKC inhibitor in HUVECs. J, summary graph of RhoA activity examined in (I). K, Peptide 2-
DPPIII for diabetic heart and kidney
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DPPIII for diabetic heart and kidneyinhibitors that lower blood glucose and HbA1c levels by
blocking glucose reabsorption from proximal tubules. Treat-
ment with canagliflozin, an SGLT2 inhibitor, for DM patients
improves heart failure and DKD (45, 46). It is clear that
improving hyperglycemia contributes to decreased morbidity
and mortality of DM. However, there are patients with
controlled blood glucose who still suffer from DM-related
complications. Therefore, it is also necessary to develop
blood-glucose-independent therapies that limit DM-induced
cardiac and renal injuries.
We demonstrated in this study that DPPIII has cardio- and
reno-protective effects in a diabetic mouse model. DPPIII
treatment in these mice did not alter the blood glucose level,
suggesting that it has a blood-glucose-independent mecha-
nism. We proposed the beneficial function of intravenously
administered DPPIII in this and previous studies (30), whereas
endogenous DPPIII has no signal sequence and principally
present in the cytosol, probably contributing to intracellular
protein catabolism (47). Extending these findings, DPPIII was
shown to have important nonenzymatic functions inside cells
(48). DPPIII regulates the Keap-1/Nrf-2 signaling pathway by
binding to Keap-1. When DPPIII binds to Keap-1, Nrf-2, a
transcription factor, is released from Keap-1 and is resistant to
ubiquitination. This promotes Nrf-2 translocation from the
cytosol into the nucleus to induce the gene expression of
antioxidant enzymes and other cytoprotective enzymes against
oxidative stress (49, 50).
In addition to DPPIII in the cells, extracellular DPPIII has
been observed and its significance is currently being investi-
gated. In the process of antigen presentation, DPPIII leaking
from necrotic cells digests and eliminates oligopeptides neces-
sary for cross-priming and activation of naïve CD8+ T cells,
preventing necrotic-cell-dependent immunogenicity and auto-
immune disorders (51). Recently, it is shown in severely burned
patients that plasma DPPIII discharged from damaged cells may
be a biomarker for an increased risk for mortality, circulatory
failure, and acute kidney injury (52). It is also reported that while
the mechanism by which DPPIII is excreted from the cytosol
remains unclear, the plasma DPPIII concentration in patients
with heart failure is associated with mortality (53). DPPIII may
act as a myocardial depressant, because DPPIII inhibition by the
monoclonal antibody Procizumab improves cardiac function in
the heart failure rodent models (53, 54). There are some
methodological discrepancies between these and our studies.
First, in the recent studies from another research group, the
protective effect of Procizumab on the heart was only examined
for the short duration (24 h), which was different from our
present study that analyzed the cardiac and renal functions for
relatively long period (8 weeks) with the repeated administra-
tion of DPPIII into mice. The long-term effect of Procizumab
has not been certified yet. Second, the circulatory and cardiacinduced U937 cell migration in the Transwell chamber coated with HUVECs in
permeability in the presence and absence of PKC inhibitor. Dashed oval indicate
effect of DPPIII on the heart and kidney. Scale bar: 20 μm (B) and 1 mm (L). In A
was applied for comparing the data between groups, and one-way ANOVA wa
concentrations or time points; in F and K, two-way ANOVA was used to compar
††p < 0.01 versus 0 min; §§p < 0.01 versus Scramble or DMSO. A.U., arbitrary uconditions in the recent experimental studies were apart from
ours. In contrast to our study, cardiac systolic function was
significantly impaired by isoproterenol injection and sever hy-
potension was induced by the septic stimulation, before treat-
ment with Procizumab was conducted in the recent studies.
These discrepancies may explain the inconsistency in the
conclusion of the recent and our studies concerning the role of
DPPIII in the cardiac and renal functions.
Moreover, in the recent studies, the mechanism by which
plasma DPPIII affects mortality and cardiac function was not
clearly presented. One of the DPPIII substrates in the plasma is
AngII, and the inhibitory effect of Procizumab on DPPIII may
result in the increase in AngII. If this is the case, it might be
inconsistent, because an excess of plasma AngII is commonly
accepted to be deteriorative for many organs including the
heart. There is a clear consensus that appropriate blockade of
the renin–AngII–aldosterone system is clinically beneficial for
the treatment of heart and/or kidney failure (55, 56). It remains
unclear in the above studies how the very low plasma DPPIII
level (pmol/l level) exerts strong bioactivities in the entire
body, and thus, further investigations are needed to address
these issues in the future.
We newly identified the peptide, Peptide 2, which was
cleaved by DPPIII and was a substrate of DPPIII in the plasma
of diabetic mice. The peptide exacerbated diabetic dysfunc-
tions in the heart and kidney in the db/db mice, but not in the
nondiabetic db/m mice. It is well known that DM (hypergly-
cemia) preferentially causes endothelial dysfunctions and
microvascular damages. Thus, vessels in diabetic animals are
fragile for additional stimulation and/or stress to induce
vascular permeability, facilitating the initiation and progres-
sion of complications in the organs (57–59). This may explain
the different pathological phenomena observed in the heart
and kidney between db/db and db/m mice, in response to
intravenous Peptide 2 administration.
Peptide 2 is a part of C3f (53% identical), and C3f can act as an
anaphylatoxin such as C3a (36). Peptide 2 transduced intra-
cellular signaling toward anaphylatoxin-like activity by inter-
acting with C3aR inHUVECs. In endothelial cells, C3aR couples
to Gα12 or Gα13, and the receptor activation induces actin stress
fiber formation through the Rho signal cascade downstream of
the G proteins (60). This may impair the endothelial function
and facilitate abnormal extravasation of inflammatory cells.
Recent findings show that loss or blockade of C3aR improves
renal dysfunction. C3aR knockout mice develop less severe
renal damage thanwild-typemice in the diabeticmodel induced
by streptozotocin administration and high-fat diet (61). Treat-
ment with a C3aR antagonist in diabetic mice limits glomerular
injury and proteinuria by preserving the podocyte density (62).
Therefore, inhibition of C3aR activation may play a protective
role in DM-induced organ damage.the presence and absence of PKC inhibitor. L, Peptide-2-stimulated vascular
s the extravasated Evans blue. M, schematic representation of the protective
, the data was analyzed by one-way ANOVA; in C, H and J, two-way ANOVA
s applied for comparing the results at 0 μmol/l or Time 0 with those at other
e the data between groups. ** p < 0.01 versus Control peptide; †p < 0.05 and
nits; P-PKC, phosphorylated PKC.
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pivotal for innate immunity (63). C3-derived molecules, such
as C3a, C3b, and C3f, have diverse bioactivities, and their
uncontrolled overactivation induces injury in tissues and or-
gans. In contrast, C3 deficiency significantly reduces renal
interstitial fibrosis by inhibiting inflammatory responses in the
mouse ureteral obstruction model (64). C3 is cleaved by C3
convertase and is divided into two fragments: C3a, a smaller
fragment and C3b, a larger fragment. Increased C3a level in
patients with chronic heart failure is clinically associated with
more frequent cardiovascular events and higher morbidity and
mortality and is a biomarker for acute-phase reaction,
inflammation, and cellular stress response (65). C3b functions
as an alternative pathway convertase by interacting with acti-
vated factor B (Bb). When the conversion of C3b to its inactive
form iC3b is suppressed, increased and overactivated C3b may
potentially confer harmful effects to organs (63). C3f is
generated on the cleavage of C3b by the function of factors H
and I. To date, the pathophysiological role of C3f has not been
extensively investigated except that a previous report demon-
strated its C3a-like anaphylatoxic activity by binding to C3aR
(36). As described above, our newly identified peptide, Peptide
2, can also exert anaphylatoxic activity, such as hyper-
permeability of microvessels in diabetic mice, through C3aR.
Because excessive activation of C3-derived molecules and their
associating molecules is causal for several renal diseases, their
inhibitors, such as a C3-targeting peptide and a factor B-
blocking compound, have been developed and are currently
under clinical evaluation (66). Accordingly, DPPIII, which
directly digests Peptide 2, may become a candidate to prevent
the progression of kidney and heart diseases.
Our study has some limitations. One of them is that the re-
sults shown in this study are obtained from the diabetic mouse
model. To extend the results in this study for the translational
research, the safety of purified DPPIII for its intravenous in-
jection into human subjects should be carefully and strictly
certified. Because DPPIII itself exists in cells in a variety of an-
imals including human, it might not be difficult to find its safety
for future human use. Another unanswered issue is that the
enzyme to produce Peptide 2 by digesting from C3f is not
identified. It is also unclear what factor is mainly involved in the
increase in Peptide 2 inDM: the enhanced activity/expression of
Peptide-2-producing enzyme(s) and/or the increased genera-
tion of Peptide 2 precursors C3f and C3b. Nonetheless, the
strong points of this study are as follows: we could propose the
beneficial effect of DPPIII on DM-induced cardiac and renal
dysfunction in a glycemic control-independent manner.
Further, we successfully identified Peptide 2, a substrate of
DPPIII, which was increased in diabetic mice, and showed the
cytotoxicity of Peptide 2 to the heart and kidney with its func-
tional mechanism. These might be useful to develop the novel
therapies against DM-related complications.
In conclusion, our findings represent the beneficial effect of
DPPIII on DM-related cardiac and renal dysfunctions. The
effect is, at least in part, dependent on DPPIII-induced cleav-
age of the plasma peptide, Peptide 2, which causes12 J. Biol. Chem. (2021) 296 100761anaphylatoxic activity through C3aR. The signaling mecha-
nism transduced by Peptide 2 includes PKC and RhoA
downstream of C3aR in endothelial cells, resulting in increased
permeability of blood vessels and damage of organs, particu-
larly in the heart and kidney. These are schematically sum-
marized in Figure 7M. Based on these results, although more
extensive experiments are required regarding translational
research, DPPIII might have potential for future clinical use in
the prevention of DM-induced cardiac and renal failures.
Experimental procedures
Cell culture and mice
HUVECs were purchased from Lonza and maintained in
Endothelial Cell Growth Medium MV 2 Kit (Takara Bio Inc).
U937 cells were purchased from American Tissue Culture
Collection and maintained in RPMI-1640 medium including
10% fetal bovine serum supplemented with 2 mmol/l gluta-
mine and an antibiotics cocktail (Nacalai Tesque). We used 8-
week-old male C57BL/6, nondiabetic (db/m; BKS.Cg-m+/
+Leprdb/Jcl) and diabetic (db/db; BKS.Cg-+Leprdb/+Leprdb/Jcl)
mice, which were purchased from CLEA Japan Inc. DPPIII
(10 μg/g body weight) or PBS was intravenously injected into
mice through the tail vein three times weekly for 8 weeks as
previously described (30). Mice were housed in specific
pathogen-free conditions in the Research Center for Animal
Life Science of Shiga University of Medical Science. The ani-
mal experiments conducted in this study were approved by
Shiga University of Medical Science Animal Care and Use
Committee and were performed in accordance with relevant
guidelines and regulations, including Animal Research
Reporting of In Vivo Experiments (ARRIVE) guidelines.
Blood pressure measurement and echocardiography
Heart rate and arterial BP were measured noninvasively
every 2 weeks during the experiment by the plethysmographic
tail-cuff method (machine model BP-98-AL, Softron) in
conscious mice, as described previously (30). Transthoracic
echocardiography was conducted every 4 weeks during the
experiment using the Vevo 2100 system (Fujifilm VisualSonics
Inc) in anesthetized mice as described previously with some
additional procedures (67). The procedure of anesthesia in
mice during echocardiography was as follows: the mice were
initially anesthetized with 2% isoflurane mixed with 2 l/min air
in the induction chamber. Then, the mice were placed on the
heating pad in the supine position, and the snout was put
within the nose cone connected to the anesthesia system to
maintain the anesthesia with 0.5% to 1.5% isoflurane mixed
with 1 l/min air. The physical condition of mice during the
echocardiography under anesthesia was checked by heart rate
monitoring (Table S1). Cardiac diastolic function was evalu-
ated by several parameters that were monitored by pulse-wave
Doppler and tissue Doppler modes. Peak early diastolic (E) and
atrial (A) transmitral inflow velocities were obtained by pulse-
wave Doppler, and early (e’) and late (atrial: a’) diastolic mitral
annular velocities were estimated by tissue Doppler imaging.
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Blood glucose concentration in mice was measured using
the Glutest sensor (Sanwa Kagaku). Plasma cholesterol and
triglyceride concentrations were analyzed using the E-test
WAKO kit (Fujifilm Wako Pure Chemical Corporation).
Mouse urine was collected for 24 h by metabolic cages every
4 weeks during the experiment. The urine samples were
analyzed by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS-PAGE), followed by Coomassie Brilliant Blue
staining to detect proteins including urinal albumin. The
visualized albumin was quantified using ImageJ software.
Histological staining and immunohistochemistry
Following euthanasia of the mice by cervical dislocation,
they were perfused with PBS, and the heart and kidney were
extracted. The extracted organs were snap-frozen in liquid
nitrogen within a block of water-soluble medium (Surgipath
FSC 22, Leica Biosystems) or fixed with 4% paraformaldehyde
and subsequently embedded in paraffin blocks. Regarding the
frozen samples, they were sectioned in 10 μm thick using a
cryostat (Leica Biosystems), fixed with 4% paraformaldehyde
on top of poly-L-lysine-coated slides, permeabilized with 0.1%
Triton X-100, and blocked with 1% bovine serum albumin
(BSA). Primary antibodies (Abs) (see below) were applied in
the BSA blocking solution at 4 C overnight, followed by 1 h
incubation at room temperature with fluorescent dye-labeled
secondary Abs. Paraffin sections, 4 μm thick, were stained
with H-E, WGA (1:500 dilution) (Thermo Fisher Scientific) or
Sirius red (1:1000 dilution) (Fujifilm Wako Pure Chemical
Corporation) using standard techniques. Confocal images were
taken using a Leica SP8 microscope (Leica Microsystems).
Images for histological analysis were captured by the BZ-X800
microscope system (Keyence). As described previously (68), at
least three random fields were selected from the four sections
in each heart to quantify the extent of fibrotic or immuno-
positive area using ImageJ software.
Staining of cultured cells
Cells grown on fibronectin-coated glass coverslips were
fixed with 4% paraformaldehyde and permeabilized with 0.2%
Triton X-100 for 5 min. To visualize F-actin and cell mem-
brane, Alexa Fluor 488-conjugated phalloidin and
tetramethylrhodamine-conjugated WGA (1:500 dilution) were
applied for 1 h at room temperature in the dark. Following
washing of the samples with PBS, nuclei were stained with
DAPI (1:500 dilution) (Dojindo) for 5 min.
Electron microscopy
The mouse kidneys were perfused with 10% formalin in
9 mmol/l sodium cacodylate, 0.05% picric acid, and 135 mmol/
l sucrose, and fixed in 4% paraformaldehyde and 2.5% glutar-
aldehyde in PBS on ice for 2 h. For scanning electron micro-
scopy, the samples were treated with 2% OsO4 in PBS for 2 h,
dehydrated in a graded series of ethanol (from 60% to 100%) at
room temperature, and soaked into 3-methylbutylacetate to be
dried completely in Critical Point Dryer (Hitachi). The driedspecimens were mounted on brass stages and coated with
ionized gold particles (20 nm) in Ion Corter IB-3 (Eiko Engi-
neering). The samples were observed in a JSM-7505FA elec-
tron microscope (JOEL Ltd) at an accelerating voltage of
10 kV. For transmission electron microscopy, the samples
were washed with PBS, treated with 2% OsO4 in PBS on ice for
2 h, dehydrated in graded ethanol, and embedded in epoxy
resin. Ultrathin sections were stained with uranyl acetate for
2 h and lead nitrate for 3 min. The samples were observed with
a Hitachi H-7500 electron microscope (Hitachi High-Tech).Experimental design for peptidomics analysis
Following an 8-week DPPIII or PBS administration, 160 U
heparin was intravenously injected in the mice, and blood
samples were collected in a tube in which ethyl-
enediaminetetraacetic acid, heparin, and phenylmethylsulfonyl
fluoride (PMSF) were added to prevent blood coagulation and
protein degradation. The plasma was obtained by centrifuga-
tion at 1000g at 4 C for 15 min and applied to reverse-phase
chromatography, followed by tandem mass spectrometry. In
detail, each plasma sample was diluted with an equal volume of
32% (v/v) acetic acid to favor disruption of peptide/protein
interactions and ultrafiltrated with a 10 kDa cutoff filter
(Centricon 10, Millipore Corp) to remove the high-molecular-
weight proteins. The filtrate was then precipitated with two
volumes of cold acetonitrile containing 0.1% of trifluoroacetic
acid to complete the removal of any residual high-molecular-
weight components. The supernatant from each sample was
then dried by Speed Vacuum (Thermo Fisher Scientific), dis-
solved in 1% (v/v) formic acid. Five microliters of the sample
was applied with Nanoflow UPLC (Easy-nLC1000, Thermo
Fisher Scientific) for performing liquid chromatography
equipped with Nanocolumn (100 μm×10 cm in-house made
column packed with a reversed-phase ReproSil-Pur C18-AQ
resin [3 μm, 12 nm, Dr Maisch GmbH]). The absorbed pep-
tides were eluted for 100 min with a linear gradient of 0.1%
formic acid in acetonitrile (solution B) against 0.1% formic acid
in water (solution A).
Subsequently, tandem mass spectrometry analyses were
carried out using Orbitrap Q Exactive HF mass spectrometry
(Thermo Fisher Scientific) with a spray voltage set to 2.2 kV
and ion transfer capillary set to 270 C. MS1 spectra were
collected in the range of 300 to 1650 m/z at 60,000 resolution
to hit an AGC target of 3 × 106. The top 20 precursor ions with
charge states of 2+ to 6+ were selected for fragmentation with
a normalized collision energy of 28%. MS2 spectra were
collected at 15,000 resolution to hit an AGC target of 1 × 105.
The dynamic exclusion time was set to 30 s. The raw data
processing and analysis by database searches were performed
with PEAKS STUDIO Desktop Version X referring 36,133 of
protein entries in the mouse UniProt database (downloaded on
November 6, 2020). The parameters of the software were set as
follows: oxidation (+15.99 Da) (histidine and tryptophan resi-
dues) and deamidation (+0.98 Da) (asparagine and glutamine
residues) were set as considered variable modifications of
proteins; nonspecific cleavages were permitted; the precursorJ. Biol. Chem. (2021) 296 100761 13
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ance was set to 0.05 Da; threshold score (Expectation value) for
accepting individual spectra was set at 15 (−10logP >15); false
discovery rate (FDR) estimation was set at 0%. To estimate
FDR in the PEAKS studio software, decoy fusion method was
applied. This peptidomics analysis was conducted by Creative
Dynamics, Inc.
Proteolytic activity assay
To determine whether DPPIII can cleave candidate peptides
detected by the peptidomics analysis, we employed a chro-
matographic technique as described previously (30). Candidate
peptides (Peptides 1–3) and a control peptide, a degradative
product of serum albumin, were generated by Biologica Co.
Each candidate peptide was dissolved in 200 μl of 50 mmol/l
sodium phosphate buffer (pH 8.0) to adjust the final concen-
tration to 50 μmol/l and was incubated with 25 nmol/l DPPIII
at 37 C. The samples were analyzed by reversed-phase
chromatographic separation on a COSMOSIL 5C18-AR-300
column (Nacalai Tesque). Chromatograms were processed
using Microsoft Excel software.Experimental design for SRM
As an internal peptide standard, stable isotope-labeled
Peptide 2 was artificially synthesized by Scrum Inc for the
mass measurement accuracy. The synthesized Peptide 2 was
labeled with [13C6,
15N] leucine at the C-terminal residue. For
preparation of plasma samples to apply to liquid chromatog-
raphy, 10 μl of 1% formic acid in water/acetonitrile (1:1), 10 μl
of the isotope-labeled Peptide 2, and 20 μl of 8 mol/l ammo-
nium formic acid were added to 50 μl of the mouse plasma
sample, which was then vigorously mixed. Subsequently,
150 μl of methanol/acetonitrile (1:1) was supplied into the
sample. High-molecular-weight proteins were removed by
centrifugation at 14,000g at 4 C for 5 min. The supernatant
from the plasma was then dried by nitrogen gas spraying and
dissolved in 1% formic acid in acetonitrile/water (1:9). Three
microliters of the sample was applied to liquid
chromatography.
SRM experiments were conducted at Kyushu Pro Search
LLC using QTRAP6500 (Sciex) coupled to ACQUITY UPLC
H-Class-liquid chromatograph (Waters). Each prepared sample
was loaded to the ACQUITY UPLC Peptide CSH C18 column
(Waters; 13 nm, 1.7 μm, 2.1 mm × 50 mm) at the flow rate of
0.4 ml/min at 50 C. The gradient elution program with mobile
phase A (0.02% (v/v) acetic acid in water) and mobile phase B
(0.02% (v/v) acetic acid in acetonitrile) was performed for the
determination of Peptide 2; 10 to 30% B for 0 to 3 min, 30% for
3 to 3.5 min, 10% for 3.5 to 4.5 min, 10 to 90% for 4.5 to 5 min,
90% for 5 to 6 min, 10% for 6 to 7 min, 10 to 90% for 7 to
7.5 min, 90% for 7.5 to 8.5 min, and 10% for 8.5 to 10 min. The
autosampler was maintained at 10 C, and the effluent was
introduced into an electrospray ionization source operated with
positive ion mode. The MS parameters in detail were as follows:
curtain gas at 25 psi, collision gas at 12 psi, IonSpray voltage at
5500 V, source temperature at 450 C, ion source gas 1 at 5014 J. Biol. Chem. (2021) 296 100761psi, ion source gas 2 at 80 psi. The SRM parameters in details
were as follows: declustering potential at 60 V, entrance po-
tential at 10 V, exit potential at 20 V, collision energy at 42 V,
and dwell time at 10 ms. SRM of the protonated precursor
molecular ions [M + 2H]2+ and the related product was
quantified. The resolutions of quadrupole Q1 mass (precursor
ion) and Q3 mass (product ion) were set at unit. For the SRM
scan of Peptide 2 in the plasma sample, ion pairs 558.0 to
698.4 m/z were monitored for quantitation, while ion pairs
558.0 to 383.2 m/z, 558.0 to 812.4 m/z, and 558.0 to 984.5 m/z
were monitored for confirmation. For the SRM scan of stable
isotope-labeled Peptide 2, ion pairs 561.5 to 698.4 m/z, 561.5 to
383.2 m/z, 561.5 to 812.4 m/z, and 561.5 to 984.5 m/z were
monitored. Chromatograms and mass spectral data were ac-
quired and processed using Analyst 1.6.2 software (Sciex).
Miles assay
This assay was performed as described previously with some
modifications (69). Briefly, 100 μl of 1% Evans blue dye
(Nacalai Tesque) dissolved in saline was intravenously injected
into mice with or without 0.2 μg/μl Gö6976, aPKC inhibitor
(Fujifilm Wako Pure Chemical Corporation). At 10 min after
the injection, 1 mmol/l Peptide 2 or control peptide was
subcutaneously injected, and the mice were euthanized 20 min
later. The subcutaneous tissue at the peptide-injected area was
observed using a stereo microscope (BioTools).
Transmigration assay
Theupper inserts (5.0μmpore size) ofChemotaxicells (Kurabo
Industries, Ltd) were coated with 100 μg fibronectin (Sigma-
Aldrich).HUVECswere seededon the insert and cultured for 48 h
to form an endothelial monolayer. Subsequently, U937 cells
(100,000 cells/100μl culturemedia)were added on themonolayer
and cultured for 6 h with Peptide 2, control peptide, or histamine
(Nacalai Tesque) added in the lower wells. The number of
U937 cells that migrated into the lower wells was counted using
the Counting chamber (ERMA Inc).
Western blotting and pull-down assay for RhoA
These experiments were performed as described previously
with some modifications (70). Briefly, total cell lysates were
obtained using the RIPA lysis buffer (50 mmol/l Tris-HCl [pH
7.5], 150 mmol/l NaCl, 0.5% deoxycholate sodium, 0.1% SDS,
1% Nonidet P-40, and 100 mM PMSF). The samples were
separated by SDS-PAGE and blotted on a polyvinylidene
difluoride membrane. The membrane was sequentially incu-
bated with primary Ab and horseradish peroxidase (HRP)-
labeled secondary Ab, followed by treatment with HRP sub-
strate (Luminata Forte, Millipore Corp). The target protein
band was observed using the luminescent image analyzer LAS-
4000 (Fujifilm Life Science). The pull-down assay was per-
formed as described previously with some modifications (71).
Briefly, the cell lysates were incubated with glutathione S-
transferase-fused mDia Rho-binding domain and glutathione-
sepharose beads (GE Healthcare) at 2 C to collect active GTP-
bound RhoA.
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Primary Abs and dilutions
Anti-CD68 rabbit polyclonal (Cat. No. ab125212) – 1:200
(Abcam), anti-nephrin guinea pig polyclonal (Cat. No. GP-N2)
– 1:300 (Progen), anti-desmin rabbit monoclonal (Clone
D93F5, Cat. No. 5332) – 1:300 (Cell Signaling Technology,
Inc), anti-CD31 rat monoclonal (Clone SZ31, Cat. No. DIA-
310) – 1:200 (Dianova), anti-podocin rabbit polyclonal (Cat.
No. P0372) – 1:500 (Sigma-Aldrich), anti-RhoA rabbit
monoclonal (Clone 67B9, Cat. No. 2117) – 1:1000 (Cell
Signaling Technology), anti-phospho-PKC rabbit polyclonal
(Cat. No. 9371) – 1:1000 (Cell Signaling Technology), and
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mouse monoclonal (clone 3H12, Cat. No. M171-3) – 1:1000
(Medical & Biological Laboratories).
Secondary Abs and dilutions
Alexa Fluor 488 or 555 goat anti-rabbit – 1:1000 (Thermo
Fisher Scientific), Alexa Fluor 488 or 555 goat anti-mouse –
1:1000 (Thermo Fisher Scientific), and HRP-linked goat anti-
rabbit IgG (Cat. No. NA934) or anti-mouse IgG (Cat. No.
NA931) Abs – 1:2000 (GE Healthcare).
Semiquantitative PCR for C3a receptor expression
The expression level of C3a receptor 1 (C3aR) was evaluated
by semiquantitative PCR. mRNA was extracted using TRIzol
RNA isolation reagent (Thermo Fisher Scientific), and cDNA
was synthesized using ReverTra Ace (Toyobo). PCR was per-
formedusing rTaqDNApolymerase (TaKaRaBio Inc). The band
densities of PCR products were quantified using the ImageJ
software. The mRNA expression level of C3aR was adjusted to
that of β-actin as an internal control. Primer sequences for the
experiments were as follows: C3aR forward 50-AGG-
CAATGGGCTGGTGCTGT-30 and reverse 50-CAGGAAGA-
CACTGGCAAACAT-30; β-actin forward 50-TCCTCCCCT
GGAGAAGAGCTA-30 and reverse 50-GAATCCTGTGGCA
TCCAC-30. To silence C3aR expression in HUVECs, siRNA
againstC3aR (#1: 50-AAGCGCTTCTAGCAATTCCT-30, #2: 50-
AAGCAGTCCATTCAGGGAATTCT-30) was transfected into
the cells with RNAiMAX (Thermo Fisher Scientific), and the
cells were cultured for 2 days.
Cell surface attachment of Peptide 2 through C3aR
FITC-conjugated Peptide 2 was generated by Biologica Co.
HUVECs, in which C3aR was or was not knocked down, were
incubated with the indicated concentrations of FITC-Peptide 2
for 2 h at 4 C. Subsequently, the cells were washed with PBS
three times and labeled with tetramethylrhodamine-WGA
(Thermo Fisher Scientific). Following fixation with 4% para-
formaldehyde, the attached peptides on the cell surface were
observed using a Leica SP8 microscope (Leica Microsystems).
Statistics
Data are expressed as mean ± standard deviation. Experi-
ments were performed at least three times independently.Statistical significance was analyzed using Prism software
(GraphPad Software) and determined by Kolmogorov–
Smirnov test, one-way analysis of variance (ANOVA), or
two-way ANOVA as appropriate. When ANOVA was signif-
icant, individual difference was evaluated using the Bonferroni
posttest. Sample sizes and statistical significance are indicated
in the figures. A value of p < 0.05 was considered to be sta-
tistically significant.
Data availability
All of the data are contained within the article. The raw
mass spectrometry and SRM data were deposited to the Pro-
teomeXchange Consortium via the PRIDE partner repository
(72), with the dataset identifiers PXD025440 for mass spec-
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